Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Share-based Compensation (2016 - 2025)

Editas Medicine (EDIT) has disclosed Share-based Compensation for 11 consecutive years, with $2.2 million as the latest value for Q3 2025.

  • Quarterly Share-based Compensation fell 53.6% to $2.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $11.9 million through Sep 2025, down 47.71% year-over-year, with the annual reading at $21.4 million for FY2024, 8.18% up from the prior year.
  • Share-based Compensation for Q3 2025 was $2.2 million at Editas Medicine, down from $2.7 million in the prior quarter.
  • The five-year high for Share-based Compensation was $13.5 million in Q2 2021, with the low at $2.2 million in Q3 2025.
  • Average Share-based Compensation over 5 years is $6.4 million, with a median of $5.3 million recorded in 2023.
  • The sharpest move saw Share-based Compensation soared 149.7% in 2021, then plummeted 60.73% in 2025.
  • Over 5 years, Share-based Compensation stood at $7.7 million in 2021, then decreased by 29.95% to $5.4 million in 2022, then fell by 0.35% to $5.3 million in 2023, then decreased by 24.79% to $4.0 million in 2024, then crashed by 44.58% to $2.2 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $2.2 million, $2.7 million, and $3.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.